Samsung Biologics Co Ltd Sustainability Reports
Samsung Biologics Co., Ltd. is a contract development and manufacturing organization (CDMO) that provides development and commercial manufacturing services for biopharmaceutical products. It specializes in cell line development, process development, and large-scale manufacturing of biopharmaceuticals such as monoclonal antibodies.
Sector: Manufacturing
Country: South Korea
Exchange: Korea Exchange (KOSPI)
FIGI: BBG0060N9DT6
3 reports from 2020 to 2024